<DOC>
	<DOCNO>NCT00616005</DOCNO>
	<brief_summary>Objective : To determine activity combo Irinotecan + Temozolomide To characterize toxicity associate w combo Irinotecan + Temozolomide</brief_summary>
	<brief_title>Ph . II Treatment Adults w Primary Malignant Glioma w Irinotecan + Temozolomide</brief_title>
	<detailed_description>Objectives study determine activity combo Irinotecan + Temozolomide &amp; characterize toxicity associate w combo Irinotecan + Temozolomide . Temozolomide administer orally 200mg/m2 fast state 1hr prior CPT-11 infusion . Temozolomide administered day 1 treatment cycle &amp; every 24hrs thereafter 5 day w treatment cycle repeat every 6wks . Treatment cycle may repeat maxi 3 cycle occurrence either unacceptable toxicity/evidence disease progression . At end 3rd cycle/if cycle stop early toxicity progression , subject undergo radiation therapy . CPT-11 administer intravenously fast state 90min . CPT-11 begin 1hr Temozolomide administration day 1 treatment cycle . CPT-11 administered day 1 , 8 , 22 , &amp; 29 6wk treatment cycle . Treatment cycle may repeat maxi 3 cycle occurrence either unacceptable toxicity/evidence disease progression . Dose CPT-11 base whether pt receive CYP3A4-inducing antiepileptic drug due increase drug clearance produce agent . For pt receive EIAEDs include phenytoin , fosphenytoin , oxcarbazepine , phenobarbital/ primidone , CPT-11 dose 325mg/m2 administer . For pt receive EIAEDs , CPT-11 dose of125 mg/m2 administer . Subjects newly diagnose histologically proven supratentorial glioblastoma multiforme . Toxicities associate w CPT-11 anemia , decrease blood count , diarrhea , constipation , nausea , vomit , tiredness , fever , mouth sore , dehydration , rash , itching , change skin color , swell , numbness , tingle , dizziness , confusion , low blood pressure , sweat , hot flash , hair loss , inflammation liver , flu-like symptom , decrease urine output , shortness breath , &amp; pneumonia . Low white blood cell &amp; platelet count may associate w risk infection/bleeding , respectively . Irinotecan also cause birth defect animal . Most frequent toxicity earlier study low white blood cell &amp; diarrhea , &amp; death see &amp; side effect . Temozolomide well tolerate adult &amp; child w common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea &amp; vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , hepatotoxicity , anorexia , fatigue &amp; hyperglycemia . Hypersensitivity reaction yet note w Temozolomide . As case w many anti-cancer drug , Temozolomide may carcinogenic .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Pts histologically proven supratentorial GBM Pts newly diagnose disease There must measurable disease contrastenhanced magnetic resonance imaging perform &lt; 14 day drug administration . Those underwent resection must MRI &lt; 72 hrs/ &gt; 14 day surgery Prior Surgical Resection/Biopsy : Although surgical resection require , pt must treat &lt; 42 day surgery biopsy Age &gt; 18 yr Karnofsky Performance Status &gt; 70 percent Serum creatinine &lt; 1.5 x ULN Absolute neutrophil count &gt; 1500 cells/microliter ; platelet count &gt; 100,000 cells/microliter Serum SGOT &amp; total bilirubin &lt; 2.5 x ULN Signed informed consent , approve IRB , obtain prior initiate treatment Pts must agree practice effective birth control measure study &amp; 2 month complete therapy Pregnant/breast feeding woman / women/men w reproductive potential practicing adequate contraception . This therapy may associate w potential toxicity fetus/child exceeds minimum risk necessary meet health need mother Active infection require intravenous antibiotic Known diagnosis HIV infection Pts w history another primary malignancy currently require active intervention Pts unwilling/unable comply w protocol due serious medical/psychiatric condition Pts underwent surgical resection GBM &lt; 2 week start treatment Pts receive prior chemo , biologic therapy , XRT , interstitial brachytherapy/radiosurgery brain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Camptosar</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
</DOC>